Literature DB >> 22160044

Myelodysplastic/myeloproliferative neoplasms.

Mario Cazzola1, Luca Malcovati, Rosangela Invernizzi.   

Abstract

According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myelodysplastic/myeloproliferative neoplasms are clonal myeloid neoplasms that have some clinical, laboratory, or morphologic findings that support a diagnosis of myelodysplastic syndrome, and other findings that are more consistent with myeloproliferative neoplasms. These disorders include chronic myelomonocytic leukemia, atypical chronic myeloid leukemia (BCR-ABL1 negative), juvenile myelomonocytic leukemia, and myelodysplastic/myeloproliferative neoplasms, unclassifiable. The best characterized of these latter unclassifiable conditions is the provisional entity defined as refractory anemia with ring sideroblasts associated with marked thrombocytosis. This article focuses on myelodysplastic/myeloproliferative neoplasms of adulthood, with particular emphasis on chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts associated with marked thrombocytosis. Recent studies have partly clarified the molecular basis of these disorders, laying the groundwork for the development of molecular diagnostic and prognostic tools. It is hoped that these advances will soon translate into improved therapeutic approaches.

Entities:  

Mesh:

Year:  2011        PMID: 22160044     DOI: 10.1182/asheducation-2011.1.264

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  22 in total

1.  Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Authors:  Luca Malcovati; Elisa Rumi; Mario Cazzola
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

2.  Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Hui Sun; Zhifen Zhang; Xiangli Li; Yuantang Li; Li Li; Rui Xu; Zie Wang; Wenjun Tian
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

3.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

Review 4.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.

Authors:  Mario Cazzola; Marianna Rossi; Luca Malcovati
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

Review 5.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

Review 6.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

7.  Molecular basis of myelodysplastic syndromes.

Authors:  M Cazzola
Journal:  Leuk Suppl       Date:  2012-08-09

8.  Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.

Authors:  Irina Triantafyllidis; Anca Ciobanu; Oana Stanca; Cecilia Draghici; Silvana Angelescu; Eliza Tapelea
Journal:  Maedica (Buchar)       Date:  2012-06

Review 9.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

10.  Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia.

Authors:  Tang-Her Jaing; Iou-Jih Hung; Shih-Hsiang Chen; Wen-I Lee; Yu-Chuan Wen; En-Chen Fang
Journal:  Int J Hematol       Date:  2012-12-22       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.